South and Central America Non-Alcoholic Steatohepatitis Market
南部和南部中美洲非酒精性脂肪性肝炎市场预计将从 2021 年的 4476 万美元增至 2028 年的 3.0388 亿美元。预计 2021 年至 2028 年该市场将以 31.5% 的复合年增长率增长。
制药公司之间合作扩大联合疗法的趋势日益明显。单一疗法可能会提供适度或模棱两可的数据，因此，现在将不再是一种有效的疗法。这是因为 NASH 复杂的病理生理学（氧化应激、炎症激活、纤维形成、微生物组、肠道通透性增加和免疫细胞机制）影响了表型的异质性。因此，尽管该报告进行了大量的后期试验，但单一疗法对 NASH 的改善似乎很复杂且不太可能。目前正在对几种药物与 Farnesoid X 受体 (FXR) 激动剂进行测试。例如，Tropifexor/CVC（艾尔建和诺华）、Semaglutide/Cilofexor/Firsocostat（诺和诺德和吉利德）和 Selonsertib/Cilofexor/Firsocostat（吉利德，现已停产）的组合。诺华正在其他药物组合试验中招募 380 名患有 2 期或 3 期纤维化的 NASH 患者，以评估 Licogliflozin（一种 SGLT1/2 抑制剂）和 Tropifexor 联合或单独进行的 2 期 ELIVATE 临床试验，预计该试验将进行到 2023 年完成。Metacrine Inc. 在一项 2a 期联合试验 (ClinicalTrials.gov NCT04702490) 中对 NASH 和 T2D 患者中的其他 FXR 激动剂 MET409 与 SGLT2 抑制剂 Empagliflozin (Jardiance) 进行了比较。辉瑞公司已适当考虑联合疗法，并在短期内与安慰剂相比，评估了 PF-06865571（一种 DGAT2 抑制剂）和 PF-05221304（一种 ACC 抑制剂）对 NAFLD 受试者全肝脂肪的影响。 - 周 2a 期临床试验 (ClinicalTrials.gov NCT03776175)。与安慰剂相比，两种药物单独或联合使用均可显着降低肝脏脂肪；然而，没有证据表明每种单一疗法与联合疗法之间没有巨大差异，具有相加性（或协同作用）。到 2020 年底，辉瑞表示 PF-05221304 不再在其管道中，并停止作为单一疗法。此外，辉瑞最近对其产品线进行了一项一期临床试验，以评估 PF-06882961 (Danuglipron)，一种 GLP-1R 激动剂与 PF-06865571 联合治疗 NASH 的效果。因此，越来越多的涉及药物组合研究的临床试验预计将成为预测期内的一种趋势。The South &预计中美洲非酒精性脂肪性肝炎市场在预测期内将以良好的复合年增长率增长。
< /p>
南和南中美洲非酒精性脂肪性肝炎市场细分
南部和南部中美洲非酒精性脂肪性肝炎市场细分为产品、应用、销售渠道和国家。根据产品类型，South &中美洲非酒精性脂肪性肝炎市场分为维生素 E 和吡格列酮、ocaliva、elafibranor、selonsertib、cenicriviroc 等。 selonsertib 和cenicriviroc 细分市场预计将成为预测期内增长最快的细分市场。中美洲非酒精性脂肪性肝炎市场细分为治疗和诊断。治疗领域以南和北地区为主。 2020年中美洲非酒精性脂肪性肝炎市场。根据销售渠道，南美和南美地区非酒精性脂肪性肝炎市场预测中美洲非酒精性脂肪性肝炎市场细分为医院药房、在线提供商和零售药房。零售药房市场以南和南地区为主。 2020 年中美洲非酒精性脂肪性肝炎市场。中美洲非酒精性脂肪性肝炎市场分为巴西、阿根廷和南美其他地区。中美洲。巴西队统治了南部和南部地区。 2020年中美洲非酒精性脂肪性肝炎市场。
Cadila Pharmaceutical、Intercept Pharmaceutical、Novartis AG、Galmed Pharmaceutical、GENFIT、Siemens Healthineers AG ，和美国实验室控股公司是南美和南美地区的领先公司之一。中美洲非酒精性脂肪性肝炎市场。
Strategic insights for South and Central America Non-Alcoholic Steatohepatitis involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 44.76 Million |
| Market Size by 2028 | US$ 303.88 Million |
| Global CAGR (2021 - 2028) | 31.5% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 产品
|
| Regions and Countries Covered | 南美洲和中美洲
|
| Market leaders and key company profiles |
The regional scope of South and Central America Non-Alcoholic Steatohepatitis refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The South and Central America Non-Alcoholic Steatohepatitis Market is valued at US$ 44.76 Million in 2021, it is projected to reach US$ 303.88 Million by 2028.
As per our report South and Central America Non-Alcoholic Steatohepatitis Market, the market size is valued at US$ 44.76 Million in 2021, projecting it to reach US$ 303.88 Million by 2028. This translates to a CAGR of approximately 31.5% during the forecast period.
The South and Central America Non-Alcoholic Steatohepatitis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Non-Alcoholic Steatohepatitis Market report:
The South and Central America Non-Alcoholic Steatohepatitis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Non-Alcoholic Steatohepatitis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Non-Alcoholic Steatohepatitis Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South and Central America Non-Alcoholic Steatohepatitis Market
